Investors Warned of Class Action Lawsuit Deadlines for Nektar Therapeutics Shares

Nektar Therapeutics Shareholder Alert

The Gross Law Firm has issued an important alert for shareholders of Nektar Therapeutics (NASDAQ: NKTR) regarding a potential securities class action lawsuit. If you purchased NKTR shares between February 26, 2025, and December 15, 2025, it’s crucial to pay attention to your rights and the actions you might need to take.

Background of the Case

During the aforementioned class period, allegations have surfaced claiming that the company made misleading statements and failed to disclose crucial information concerning the enrollment process in their REZOLVE-AA trial. Key issues include:

1. Enrollment Protocol Violations: The complaint states that the enrollment did not adhere to set instructions and protocol standards, raising questions about the reliability of the trial results.
2. Impact on Trial Integrity: It is asserted that these violations likely had a significant negative impact on the results of the REZOLVE-AA trial, potentially skewing data and misleading investors about the trial's integrity.
3. Misleading Public Statements: As a direct consequence of these failures, the public statements made by Nektar during this period are claimed to have been materially false and misleading.

Deadline for Action

Investors are urged not to delay in registering for the class action as the lead plaintiff application deadline is set for May 5, 2026. However, it is important to note that appointment as the lead plaintiff is not a requirement to receive potential recovery as a member of the class.

For those who wish to secure their stake in this matter, you can register your information by visiting the Gross Law Firm's website provided in the alert. Once registered, shareholders will also be enrolled in a portfolio monitoring service that sends updates regarding the ongoing litigation proceedings.

Why Choose Gross Law Firm?

The Gross Law Firm is a reputable class action law firm committed to safeguarding the rights of investors. Their mission focuses on ensuring that companies uphold ethical business practices and are held accountable for any fraudulent activities that result in financial loss to their shareholders. By representing clients in these cases, they aim to recover losses incurred due to misleading statements or critical omissions by companies.

Final Thoughts

If you own shares of Nektar Therapeutics and fall within the specified period of purchase, it's crucial to act swiftly. Protect your interests and stay informed about your rights as an investor. Should you have any inquiries or require further information, you can reach out to the Gross Law Firm’s contact details listed in their alert.

For legal representation regarding this matter, or if you have further questions about your rights as an investor in Nektar Therapeutics, ensure that you act before the looming deadline arrives.

Contact Information
The Gross Law Firm
15 West 38th Street, 12th Floor
New York, NY 10018
Email: [email protected]
Phone: (646) 453-8903